We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Pilot Study in Patients With Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01257958
Recruitment Status : Completed
First Posted : December 10, 2010
Last Update Posted : October 5, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.

Condition or disease Intervention/treatment Phase
Relapsing Remitting Multiple Sclerosis Drug: 19 nor vitamin d Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Vitamin D Pilot Study in Patients With Multiple Sclerosis
Study Start Date : February 1998
Primary Completion Date : February 2000
Study Completion Date : June 2000

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 19 nor vitamin d Drug: 19 nor vitamin d


Outcome Measures

Primary Outcome Measures :
  1. MRI Measure of new active lesions, observation vs. treatment

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • relapsing remitting MS

Exclusion Criteria:

  • MRI contraindicated
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257958


Locations
United States, Wisconsin
UW-Madison
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
More Information

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT01257958     History of Changes
Other Study ID Numbers: HSC #97-676-311
First Posted: December 10, 2010    Key Record Dates
Last Update Posted: October 5, 2015
Last Verified: December 2010

Keywords provided by University of Wisconsin, Madison:
Vitamin D, 19 nor Vitamin D, Multiple Sclerosis

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Vitamins
Vitamin D
Ergocalciferols
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents